Products
Cologuard test
A noninvasive stool test that screens for colorectal cancer in adults 45 and older at average risk. Available by prescription only.
Shaping the future of cancer testing
With our new colleagues, we’re working toward an all-important goal: advancing earlier cancer detection and personalized treatment decisions for millions of people.
Together, we will accelerate innovation and expand access to our life-changing tests, which include Cologuard, Cologuard Plus, Cancerguard, Oncotype DX and Oncodetect.
Our cancer care portfolio
We answer cancer’s toughest questions with people-centered cancer screening and tests designed to impact lives.
We’re shaping the future of cancer detection and treatment
- A leading provider of cancer screening and diagnostic tests, with more than 5.5 million people tested in 2025
- Comprehensive test portfolio spanning early detection, treatment guidance, disease monitoring and therapy selection
- Breakthrough science. Expert collaboration. Uncompromising research. Delivering trusted accuracy and advancing the fight against cancer.
FAQs
Why did Abbott decide to acquire Exact Sciences?
Abbott and Exact Sciences share a purpose to help people live fuller lives through better health. Exact Sciences brings industry‑leading expertise in molecular oncology and early cancer detection, which complements Abbott’s global scale, scientific leadership, and broad diagnostics portfolio.
Together, we will expand access to advanced cancer testing, accelerate innovation, and enhance patient care around the world.
Does anything change for customers with the acquisition?
We do not anticipate any near‑term changes for customers. Our priority is maintaining business continuity and ensuring the same high level of service.
Will current products still be offered?
Yes, Exact Sciences’ current portfolio of products and services remains the same.
Does this affect insurance coverage or billing?
There are no changes to insurance coverage, billing procedures, or financial support programs because of this transaction. Customers and patients should continue to follow the same steps they follow today.